Grants for Public housing authorities - Federal

This Notice of Funding Opportunity (NOFO) invites applications for a cooperative agreement to support, manage and facilitate Public-Private Partnerships and Collaborative activities as part of the Critical Path Initiative and to support regulatory science efforts. FDA and grantees will work together to develop innovative, collaborative projects in research, education, and outreach. These projects can help foster drug product innovation to 1) support efforts to accelerate drug product development; 2) support approaches to advanced manufacturing; 3) facilitate translation of basic science discoveries into therapeutics; and 4) facilitate approaches to enhance the safety, efficacy, quality, and performance of drug products. Projects are identified by FDA. Multiple awards may be funded under this NOFO and are directly dependent on drug development priorities and subject to the availability of funding.

This grant provides financial support for early-career researchers in dental, oral, and craniofacial fields to receive mentorship and develop their research skills, with a focus on enhancing diversity in the research workforce.

This funding opportunity provides financial support for organizations to create transitional housing and comprehensive services for homeless youth aged 16 to 21, helping them achieve self-sufficiency and stable living conditions.

This funding opportunity provides $1 million to support a national coordinating center that will enhance collaboration, education, and research initiatives in nonmalignant hematology, targeting a diverse range of eligible institutions.

This funding opportunity supports community-driven research projects that assess environmental exposures and develop public health interventions to address health disparities in affected communities.

With this solicitation, BJA seeks to fund state, local, and tribal governments to enhance or implement evidence-based activities or services to improve reentry and reduce recidivism by expanding and/or increasing access to housing for people who are currently or formerly involved in the criminal justice system. Prior to the release of incarceration, individuals will be screened, assessed, and identified for program participation. The program will help jurisdictions assess their reentry systems, identify strengths and gaps, and then build capacity for improved housing options for adults released from prison or jail.

This grant provides funding for innovative research on immune mechanisms at mucosal surfaces in the respiratory, gastrointestinal, and urogenital tracts, aimed at advancing the understanding of mucosal immunology.

This funding opportunity provides financial support to small businesses and organizations developing innovative medical technologies and digital health solutions to improve health outcomes.

This funding opportunity announcement (FOA) is a reissue due to an omission of TRAINING RECORD review questions in Section V. This FOA encourages applications for the Chronic, Non-Communicable Diseases and Disorders Across the Lifespan: Fogarty International Research Training Award (NCD-LIFESPAN) D43 program for institutional research training programs in low-and middle-income countries (LMICs, as defined by the World Bank classification system). Applications may be for collaborations between institutions in the U.S and an eligible LMIC or may involve just LMIC institutions if there is a previous track record of externally funded research and/or research training programs by the lead LMIC institution. The proposed institutional research training program is expected to sustainably strengthen the NCD research capacity of the LMIC institutions, and to train in-country experts to develop and conduct research on NCDs across the lifespan, with the long-range goal of developing and implementing evidence-based interventions relevant to their countries. The main focus of research training covered in the application must be relevant to the interests of at least one of the participating NIH ICs as stated by each in this FOA. Other NCD topics may be included as secondary and complementary focus areas. This Funding Opportunity Announcement (FOA) allows support of trainees as the lead investigator of an independent clinical trial; or a separate ancillary study to an existing trial; or to gain research experience in a clinical trial led by another investigator, as part of their research and career development.

The "Mechanisms of Inducing HIV Immunity in Early Life (MIEL)" grant is a funding opportunity that supports research aimed at understanding and developing methods to establish and maintain immunity against HIV in children from birth to less than 12 years old, with a focus on the use of vaccines and antibodies, and the influence of maternal factors and vaccine adjuvants.

This funding opportunity supports researchers exploring the ethical, legal, and social issues related to human genetic and genomic research, particularly as these technologies become more integrated into healthcare and society.

The purpose of this Funding Opportunity Announcement (FOA) is to correlate immune system development patterns between two or more age groups - neonates, infants, and children and adolescents and further understand the impact of infectious diseases, microbiome and environmental factors on the ontogeny and development of the pediatric immune system, from birth, transitioning into adolescence and adulthood with the focus of impact during pregnancy and post-natal period.Purpose The purpose of this Funding Opportunity Announcement (FOA) is to correlate immune system in general and development patterns in particular, between two or more age groups - neonates, infants, and children and adolescents and further understand the impact of infectious diseases, microbiome and environmental factors on the ontogeny and development of the pediatric immune system, from birth, transitioning into adolescence and adulthood with the focus of impact during pregnancy and post-natal period. Background Worldwide, mortality in children under the age of 5 is predominantly due to infectious diseases and immune modulations associated with these infections. Pediatric immune system is remarkably different from adult immune system and also forms the basis for overall wellbeing and providing an adequate disease encountering status to adulthood. A protected and systematically trained pediatric immune system results in a robust and efficient adult immune system. Moreover, immune system in children responds strongly, rapidly and robustly in comparison to adult immune system to immunization, diet and environmental factors. Knowledge of development of the pediatric immune system in response to exposure to childhood infections and vaccinations, microbiome and the environmental factors can help chart pathways that provide strategies to prevent and treat infectious diseases more efficiently. These variations between pediatric and adult immune systems offer insight into better understanding strategies for developing immune-therapeutics and vaccines against infections. The research focus in the current announcement is multi-disciplinary. The focus however is in the areas of immune ontogeny and development, the mechanisms of infant and neonatal immunity or relationship between ontogeny of immunosuppression, susceptibility to infection during infancy or studies on effect of early infections or vaccinations that train the immune system. It is expected to diversify areas in existing research and draw comparisons between age groups or specific organ system development (for example, projects of interest might investigate immune cell ontogeny in lung alveoli from infancy to adult hood or immune alterations due to exposure to a specific immunogen (like measles or BCG vaccine) at infancy vs adolescence and the chronic effect of air pollution). More specifically, the aim here is to elucidate immune system development patterns in infants, children and adolescents focusing on both the innate immunity and the development of diverse antibodies or T cell maturation, with relevance to chronic infections (not limited to HIV, CMV, TB and the current SARS-CoV2 pandemic as well). Further, the intention is to expand the science to include additional internal factors like microbial metabolites and/or external factors like the environment that modulate the developing immune system so that a research program that is multi-disciplinary can be developed to address the interaction between host and pathogen. Research Scope The over-arching scope of this FOA is: to correlate immune system in general and development patterns in particular, between two or more age groups - neonates, infants, and children and adolescents to understand the evolution or immune ontogeny in human immune system development focusing on either or both, innate and adaptive immune systems with additional focus on internal factors like the microbiome and/or external factors like the environment. Further, the scope can be covered under these following topics and is not limited to: Study in young children vs adolescents vs adults, development of immunity and variations in immune system in physiology and in response to infectious diseases focusing on MTCT diseases (HIV, CMV, TB, Syphilis, SARS-CoV2 etc.), not limited to, broadly neutralizing antibodies (bNAbs), development of mucosal antibodies, germinal center formation and maturation; correlate with T cell development and identification of immunogens that activate T cells without enhancing infection. Characterize the impact of age, environmental factors, microbial metabolites and microbiome composition in relation to the immune responses against acute or chronic infectious diseases not limited to HIV, TB, CMV, SARS-CoV2 etc., and their contribution towards the development of a robust immune system development using novel technologies (RNA seq, imaging of immunogens and cellular interactions, single cell imaging). Understand cellular and soluble immune system components and the developmental pathways, including the microbiome, that regulate these components in specific age-groups. For example, developing immune profiles of HIV exposed un-infected (HEU) infants in comparison with the immune profile of an adolescent living with HIV and how these immune alterations prepare the immune system to encounter future infections. Study the contribution of increased exposure to environmental factors, pathogens, extensive or scheduled immunization early in life on enhanced cross-talk between innate and adaptive immune systems; specific inflammatory responses generated by innate immune factors and their downstream effect on cellular immune development. Delineate the role of human microbiome in health and disease and the environmental factors to observe correlation of immune responses against acute and chronic infections and focus on transfer of microbes and immune factors from human milk to infants. For example, assess alterations in immune profiles of known oral microbial clusters in CMV infected child vs immune profiles in an adolescent. Understand the impact of variations of microbiome in specific organ systems (gut vs oral vs vaginal microbiomes) in age defined profiles and their effect on immune ontogeny with emphasis on Virome . Influence of maternal microbiome on the effect of microbial composition and development of immunity in the offspring; detailed studies exploring placental microbiome and correlation with maternal oral microbial microbiome are encouraged. Projects that will be considered non-responsive for this FOA include, but are not limited to: Applications proposing vaccine advocacy. Applications proposing to focus exclusively on effects of microbiome and not studying the relevance of these effects on immune system development. Applications proposing to focus exclusively on epigenomic approaches. Applications focusing on immunization strategies in infants for altering early immune responses.

This grant provides funding for research projects aimed at improving the diagnosis and treatment of health conditions related to the September 11, 2001, terrorist attacks, specifically for individuals who were exposed in New York City and surrounding areas.

This grant provides funding to strengthen the management and evaluation of human resources in Malawi's national HIV and TB programs, focusing on hiring skilled personnel to support epidemic control efforts.

This funding opportunity supports multidisciplinary research teams in the U.S. working on complex biomedical questions, with a focus on advancing foundational biological processes and addressing critical health issues.

The "Facilitating Preclinical and Early Phase Human Studies for New Therapeutics" grant aims to fund research that advances new treatments from preclinical stages to first-in-human trials for aging-related conditions, excluding neurodegenerative and Alzheimer's diseases, with a focus on improving injury repair in older adults and defining clear milestones for progress monitoring.

This grant provides funding to early-stage researchers exploring innovative chemical and pharmacological approaches to understanding and treating substance use disorders.

The STRIPE program grant is designed to fund pre-clinical research that explores how radiopharmaceutical therapy affects cancer cells and their environment, with the aim of developing new targeting strategies and informing the design of future RPT-based clinical trials.

This funding opportunity supports innovative interventions to improve the health and quality of life for people living with HIV, particularly those from racial and ethnic minority populations and low-income backgrounds, by addressing related health issues and promoting successful aging.

This funding opportunity supports innovative research projects aimed at improving mental health services and addressing disparities in access and quality, particularly for underserved populations.